| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de Charles River Laboratories International, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$239.43 |
| 52 Week High | US$275.00 |
| 52 Week Low | US$161.65 |
| Beta | 1.41 |
| 1 Month Change | -9.86% |
| 3 Month Change | 12.39% |
| 1 Year Change | 28.03% |
| 3 Year Change | -28.49% |
| 5 Year Change | 74.31% |
| Change since IPO | 988.32% |
Noticias y actualizaciones recientes
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11
Recent updates
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Charles River raised to Buy at Jefferies on prospects for animal studies
Sep 30Rentabilidad de los accionistas
| CRL | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 4.1% | 4.1% | 1.2% |
| 1Y | 28.0% | 4.7% | 24.9% |
Rentabilidad vs. Industria: CRL superó al sector US Life Sciences , que obtuvo un rendimiento del -6.7% el año pasado.
Rentabilidad vs. Mercado: CRL superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| CRL volatility | |
|---|---|
| CRL Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CRL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CRL (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. ofrece servicios de descubrimiento de fármacos, desarrollo no clínico y pruebas de seguridad en Estados Unidos, Europa, Canadá, Asia-Pacífico e internacionalmente. Opera a través de tres segmentos: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) y Manufacturing Solutions (Manufacturing). El segmento RMS produce y vende roedores, así como ratas y ratones reproducidos para uso de los investigadores.
Resumen de fundamentos de Charles River Laboratories International, Inc.
| Estadísticas fundamentales de CRL | |
|---|---|
| Capitalización bursátil | US$12.33b |
| Beneficios(TTM) | US$474.62m |
| Ingresos (TTM) | US$4.13b |
25.9x
Ratio precio-beneficio (PE)3.0x
Ratio precio-ventas (PS)¿Está CRL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CRL | |
|---|---|
| Ingresos | US$4.13b |
| Coste de los ingresos | US$2.60b |
| Beneficio bruto | US$1.53b |
| Otros gastos | US$1.05b |
| Beneficios | US$474.62m |
Últimos beneficios comunicados
Dec 30, 2023
Próxima fecha de beneficios
May 09, 2024
| Beneficios por acción (BPA) | 9.24 |
| Margen bruto | 37.03% |
| Margen de beneficio neto | 11.49% |
| Ratio deuda/patrimonio | 71.7% |
¿Cómo se ha desempeñado CRL a largo plazo?
Ver rendimiento histórico y comparativa